Sign in
CompletedPhase 1

Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Key facts

Who runs it
Mayo Clinic
Where
Jacksonville, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1
People taking part
3 people enrolled
Started
15 Sept 2021
Ended
16 Feb 2024
Type of study
Interventional, 3 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Plasmapheresis
  • Plasma infusion
Record updated
31 December 2024

Who can take part

Age
50 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 25 criteriaShow less

Who can take part

  • Patient age 50 to 75
  • APOE 44 homozygote
  • Meets the Petersen criteria for MCI (41)
  • Clinical Dementia Rating (CDR) of 0.5 and Mini Mental Status Examination (MMSE) of 24 to 30 inclusive
  • Has an informant who the investigator judges has sufficient patient contact to provide accurate information
  • Stable depression and or anxiety
  • Stable psychoactive medication for 6 weeks

Who cannot take part

  • No venous access for plasma exchange therapy
  • History of severe reaction to plasma or plasma derived products which include but not limited to severe allergic reaction, anaphylactic reaction and transfusion related acute lung injury (TRALI)
  • Has a medical condition that would interfere with participation such as congestive heart failure (New York Heart Association Class III or IV), unstable angina, moderate to severe renal impairment, liver failure, and poorly controlled diabetes
  • History of autoimmune disease considered clinically significant or requiring chronic steroid or immune suppression medication
  • History of being HIV +
  • History of +VE test result indicating active hepatitis C or B (defined as both hepatitis B surface antigen and hepatitis core antibody +VE)
  • Uncontrolled hypertension as defined by systolic/diastolic BP three times more than 165/100
  • Any neurological condition that could be contributing to cognitive decline such as Lewy body disease, front temporal dementia, strokes or other cerebrovascular disease, head trauma, substance abuse, multiple sclerosis, Vitamin B12 deficiency, thyroid deficiency
  • Epileptic seizures within 10 years of screening
  • Cancer diagnosis (other than non-melanoma skin cancer) in the last 5 years
  • More than 1 subcortical stroke or more than 1 cortical stroke
  • MRI showing acute or subacute hemorrhage, evidence of normal pressure hydrocephalus, hemispheric infarcts, glioma or other brain tumor that could contribute to cognitive decline
  • Unstable psychiatric condition
  • If a patient consents to lumbar puncture (LP), they will be excluded from LP if any contraindication to having an LP is present. Examples are platelet count<100,000, spine deformity or contraindication to come off blood thinner for the LP. Patients may still participate in the rest of the study without having and LP
  • Patients who do not want to receive blood transfusion for religious or cultural reasons such as Jehovah Witness Faith
  • Unable to have an MRI
  • On another experimental treatment study or has been on one in the last 3 months
  • Any unspecified reason that the investigator finds the patient unsuitable to take part

Where in United States

  • Mayo Clinic in FloridaJacksonville, United States

About the trial

What the trial wants to find out

Determine safety of plasma infusion or exchange in APOE 44 patients.

The 3 groups in the trial

  • PlasmapheresisTreatment being tested

    3 patients will have monthly plasmapheresis for 6 months and followed for a total of 12 months

  • Plasma infusionTreatment being tested

    3 patients will have biweekly plasma infusion for 6 months and followed for 12 months

  • Control groupNo study treatment, for comparison

    3 patients will be followed for 12 months

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression: an Unblinded Phase 1 Safety, Methodological and Exploratory Biomarkers Study.
Record updated
31 December 2024